[Form 4] ADT Inc. Insider Trading Activity
Ligand Pharmaceuticals Inc. (LGND) filed a Form 144 indicating a planned disposition of common shares. The notice covers the proposed sale of 934 shares through UBS Financial Services, Inc. at an aggregate market value of $116,750, representing approximately 0.0048 % of the company鈥檚 19,294,168 shares outstanding. The anticipated sale date is 07 / 10 / 2025. The seller originally acquired the shares in separate transactions on 06 / 06 / 2019 and 06 / 04 / 2021 directly from the issuer. No other sales were reported for the past three months, and no material adverse information is acknowledged by the filer as required under Rule 144.
Ligand Pharmaceuticals Inc. (LGND) ha presentato un modulo 144 che indica una prevista cessione di azioni ordinarie. L鈥檃vviso riguarda la proposta vendita di 934 azioni tramite UBS Financial Services, Inc. per un valore complessivo di mercato di 116.750 $, pari a circa il 0,0048 % delle 19.294.168 azioni in circolazione della societ脿. La data prevista per la vendita 猫 il 10/07/2025. Il venditore ha originariamente acquisito le azioni in transazioni separate il 06/06/2019 e il 04/06/2021 direttamente dall鈥檈mittente. Negli ultimi tre mesi non sono state segnalate altre vendite e il dichiarante non ha riconosciuto alcuna informazione negativa rilevante come richiesto dalla Regola 144.
Ligand Pharmaceuticals Inc. (LGND) present贸 un Formulario 144 indicando una disposici贸n planificada de acciones comunes. El aviso cubre la venta propuesta de 934 acciones a trav茅s de UBS Financial Services, Inc. con un valor de mercado agregado de $116,750, que representa aproximadamente el 0,0048 % de las 19,294,168 acciones en circulaci贸n de la compa帽铆a. La fecha anticipada de venta es el 10/07/2025. El vendedor adquiri贸 originalmente las acciones en transacciones separadas el 06/06/2019 y el 04/06/2021 directamente del emisor. No se reportaron otras ventas en los 煤ltimos tres meses y el declarante no reconoce informaci贸n adversa material seg煤n lo requerido por la Regla 144.
Ligand Pharmaceuticals Inc. (LGND)電� 氤错喌欤� 觳橂秳 瓿勴殟鞚� 雮橅儉雮措姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞚� 韱奠電� UBS Financial Services, Inc.毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $116,750鞐� 頃措嫻頃橂姅 934欤�鞚� 毵り皝 鞓堨爼 瓯挫潉 韽暔頃橂┌, 鞚措姅 須岇偓鞚� 19,294,168欤� 氚滍枆 欤检嫕鞚� 鞎� 0.0048%鞐� 頃措嫻頃╇媹雼�. 鞓堨儊 毵り皝鞚检潃 2025雲� 7鞗� 10鞚�鞛呺媹雼�. 毵る弰鞚胳潃 2019雲� 6鞗� 6鞚缄臣 2021雲� 6鞗� 4鞚检棎 氚滍枆靷攵�韯� 氤勲弰搿� 欤检嫕鞚� 旆摑頄堨姷雼堧嫟. 歆�雮� 3臧滌洈 霃欖晥 雼るジ 毵り皝鞚� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞁犼碃鞛愲姅 攴滌箼 144鞐� 霐半澕 欷戩殧頃� 攵�鞝曥爜 鞝曤炒毳� 鞚胳爼頃橃 鞎婌晿鞀惦媹雼�.
Ligand Pharmaceuticals Inc. (LGND) a d茅pos茅 un formulaire 144 indiquant une cession pr茅vue d鈥檃ctions ordinaires. L鈥檃vis concerne la vente propos茅e de 934 actions par l鈥檌nterm茅diaire de UBS Financial Services, Inc. pour une valeur marchande totale de 116 750 $, repr茅sentant environ 0,0048 % des 19 294 168 actions en circulation de la soci茅t茅. La date de vente pr茅vue est le 10/07/2025. Le vendeur a initialement acquis les actions lors de transactions distinctes les 06/06/2019 et 04/06/2021 directement aupr猫s de l鈥櫭﹎etteur. Aucune autre vente n鈥檃 茅t茅 signal茅e au cours des trois derniers mois et le d茅clarant ne reconna卯t aucune information d茅favorable importante conform茅ment 脿 la r猫gle 144.
Ligand Pharmaceuticals Inc. (LGND) hat ein Formular 144 eingereicht, das eine geplante Ver盲u脽erung von Stammaktien anzeigt. Die Mitteilung betrifft den geplanten Verkauf von 934 Aktien 眉产别谤 UBS Financial Services, Inc. zu einem Gesamtmarktwert von 116.750 $, was etwa 0,0048 % der 19.294.168 ausstehenden Aktien des Unternehmens entspricht. Das erwartete Verkaufsdatum ist der 10.07.2025. Der Verk盲ufer erwarb die Aktien urspr眉nglich in getrennten Transaktionen am 06.06.2019 und 04.06.2021 direkt vom Emittenten. In den letzten drei Monaten wurden keine weiteren Verk盲ufe gemeldet und der Einreicher erkennt keine wesentlichen nachteiligen Informationen gem盲脽 Regel 144 an.
- None.
- None.
Insights
TL;DR: Routine Form 144 for 934 LGND shares (~$117k); negligible 0.005 % of float鈥攏o material impact on valuation or liquidity.
The filing signals an insider鈥檚 intent to sell 934 LGND common shares via UBS on or about 10 July 2025. At roughly one-twentieth of one percent of outstanding stock, the trade is immaterial to daily volume and unlikely to influence price discovery. No pattern of sustained selling is evident, as the filer reported no other dispositions within the last three months. Because Form 144 precedes, rather than confirms, an actual transaction, investors should view it as a routine compliance step rather than a firm indication of bearish sentiment. Overall impact is neutral.
Ligand Pharmaceuticals Inc. (LGND) ha presentato un modulo 144 che indica una prevista cessione di azioni ordinarie. L鈥檃vviso riguarda la proposta vendita di 934 azioni tramite UBS Financial Services, Inc. per un valore complessivo di mercato di 116.750 $, pari a circa il 0,0048 % delle 19.294.168 azioni in circolazione della societ脿. La data prevista per la vendita 猫 il 10/07/2025. Il venditore ha originariamente acquisito le azioni in transazioni separate il 06/06/2019 e il 04/06/2021 direttamente dall鈥檈mittente. Negli ultimi tre mesi non sono state segnalate altre vendite e il dichiarante non ha riconosciuto alcuna informazione negativa rilevante come richiesto dalla Regola 144.
Ligand Pharmaceuticals Inc. (LGND) present贸 un Formulario 144 indicando una disposici贸n planificada de acciones comunes. El aviso cubre la venta propuesta de 934 acciones a trav茅s de UBS Financial Services, Inc. con un valor de mercado agregado de $116,750, que representa aproximadamente el 0,0048 % de las 19,294,168 acciones en circulaci贸n de la compa帽铆a. La fecha anticipada de venta es el 10/07/2025. El vendedor adquiri贸 originalmente las acciones en transacciones separadas el 06/06/2019 y el 04/06/2021 directamente del emisor. No se reportaron otras ventas en los 煤ltimos tres meses y el declarante no reconoce informaci贸n adversa material seg煤n lo requerido por la Regla 144.
Ligand Pharmaceuticals Inc. (LGND)電� 氤错喌欤� 觳橂秳 瓿勴殟鞚� 雮橅儉雮措姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 鞚� 韱奠電� UBS Financial Services, Inc.毳� 韱淀暣 齑� 鞁滌灔 臧�旃� $116,750鞐� 頃措嫻頃橂姅 934欤�鞚� 毵り皝 鞓堨爼 瓯挫潉 韽暔頃橂┌, 鞚措姅 須岇偓鞚� 19,294,168欤� 氚滍枆 欤检嫕鞚� 鞎� 0.0048%鞐� 頃措嫻頃╇媹雼�. 鞓堨儊 毵り皝鞚检潃 2025雲� 7鞗� 10鞚�鞛呺媹雼�. 毵る弰鞚胳潃 2019雲� 6鞗� 6鞚缄臣 2021雲� 6鞗� 4鞚检棎 氚滍枆靷攵�韯� 氤勲弰搿� 欤检嫕鞚� 旆摑頄堨姷雼堧嫟. 歆�雮� 3臧滌洈 霃欖晥 雼るジ 毵り皝鞚� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞁犼碃鞛愲姅 攴滌箼 144鞐� 霐半澕 欷戩殧頃� 攵�鞝曥爜 鞝曤炒毳� 鞚胳爼頃橃 鞎婌晿鞀惦媹雼�.
Ligand Pharmaceuticals Inc. (LGND) a d茅pos茅 un formulaire 144 indiquant une cession pr茅vue d鈥檃ctions ordinaires. L鈥檃vis concerne la vente propos茅e de 934 actions par l鈥檌nterm茅diaire de UBS Financial Services, Inc. pour une valeur marchande totale de 116 750 $, repr茅sentant environ 0,0048 % des 19 294 168 actions en circulation de la soci茅t茅. La date de vente pr茅vue est le 10/07/2025. Le vendeur a initialement acquis les actions lors de transactions distinctes les 06/06/2019 et 04/06/2021 directement aupr猫s de l鈥櫭﹎etteur. Aucune autre vente n鈥檃 茅t茅 signal茅e au cours des trois derniers mois et le d茅clarant ne reconna卯t aucune information d茅favorable importante conform茅ment 脿 la r猫gle 144.
Ligand Pharmaceuticals Inc. (LGND) hat ein Formular 144 eingereicht, das eine geplante Ver盲u脽erung von Stammaktien anzeigt. Die Mitteilung betrifft den geplanten Verkauf von 934 Aktien 眉产别谤 UBS Financial Services, Inc. zu einem Gesamtmarktwert von 116.750 $, was etwa 0,0048 % der 19.294.168 ausstehenden Aktien des Unternehmens entspricht. Das erwartete Verkaufsdatum ist der 10.07.2025. Der Verk盲ufer erwarb die Aktien urspr眉nglich in getrennten Transaktionen am 06.06.2019 und 04.06.2021 direkt vom Emittenten. In den letzten drei Monaten wurden keine weiteren Verk盲ufe gemeldet und der Einreicher erkennt keine wesentlichen nachteiligen Informationen gem盲脽 Regel 144 an.
FAQ
How many Ligand Pharmaceuticals (LGND) shares are covered by this Form 144?
What is the aggregate market value of the shares noted in the filing?
When is the approximate sale date for the LGND shares?
What percentage of Ligand鈥檚 outstanding shares does this sale represent?
Which broker is handling the proposed LGND share sale?
